3rd Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases Issues related to COVID-19 H.R.5376 - Inflation Reduction Act of 2022 Issues related to Cancer Moonshot 340B Drug Discount Program Issues related to PDUFA and pharmaceutical IP

LobbyistCovered position, as disclosed
LAURA JOHNSON BOLLIER —
NADEAM ELSHAMI —
EMILY FELDER —
MARC LAMPKIN —
R. JAMES NICHOLSON Secretary Dept of Veterans Affairs; Ambassador to Holy See Dept of State
ZACHARY PFISTER —
ADAM STEINMETZ Policy Advisor at House Budget Committee
BRIAN WILD —

Contacted: White House Office; Executive Office of the President (EOP)

Bills named: H.R. 5376 (117th)

Veterans VET

Opportunities for health care collaboration

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
MARC LAMPKIN —
ZACHARY PFISTER —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.